Pharmaceutical compositions targeting WNT pathway proteins
US10328120B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 28, 2016 |
| Grant date | Jun 25, 2019 |
| Priority date | — |
| Expiry date | Jan 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/71
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.